Arsenic Hijacks RNA Methylation to Fuel Skin Cancer — Then Creates a Vulnerability
A taurine transporter epigenetically upregulated by arsenic drives malignant skin cell transformation but simultaneously sensitizes cancer cells to copper-induced death.
Summary
Chronic arsenic exposure is a global skin cancer risk, but the molecular mechanisms linking it to metabolic changes have been unclear. This study found that arsenic exposure elevates intracellular taurine in keratinocytes by upregulating the taurine transporter SLC6A6 — a process driven by m6A RNA methylation via METTL3 and YTHDF1. The extra taurine boosts mitochondrial energy production through cytochrome c oxidase II (MT-CO2), fueling malignant transformation. Crucially, this same pathway increases copper utilization, making transformed cells unexpectedly vulnerable to cuproptosis — a copper-dependent form of cell death. The findings reveal a novel epitranscriptomic-metabolic axis in arsenic carcinogenesis and suggest that cuproptosis-inducing agents could selectively target arsenic-transformed skin cells.
Detailed Summary
Arsenic contamination in drinking water affects hundreds of millions of people worldwide and is a well-established cause of skin cancer. Yet the precise molecular steps connecting arsenic exposure to malignant transformation — particularly at the epigenetic and metabolic levels — have remained incompletely understood. This study addresses that gap by uncovering a previously unrecognized RNA methylation–metabolism axis driving arsenic-induced keratinocyte transformation.
Researchers established keratinocyte transformation models using environmentally relevant arsenite concentrations, then validated findings in mouse models and human samples. They identified elevated intracellular taurine as a consistent metabolic hallmark of arsenite-induced transformation. The taurine transporter SLC6A6 was found to be upregulated, driving increased taurine uptake into cells undergoing malignant change.
Mechanistically, the extra taurine enhanced oxidative phosphorylation by upregulating mitochondrial cytochrome c oxidase II (MT-CO2), providing the energy demands of rapidly transforming cells. The upstream driver of SLC6A6 upregulation was identified as METTL3, an m6A methyltransferase that adds N6-methyladenosine marks to SLC6A6 mRNA at multiple sites. The m6A reader protein YTHDF1 then binds these marks, stabilizing the mRNA and boosting its translation — a classic epitranscriptomic amplification loop.
A striking secondary finding was that the same MT-CO2-dependent copper utilization pathway sensitizes arsenite-transformed keratinocytes to cuproptosis — a recently characterized form of copper-dependent, oxidative-phosphorylation-driven cell death. This creates a potential therapeutic window: the very metabolic reprogramming that drives malignancy also generates a selective vulnerability.
Caveats include reliance on cell and mouse models, with limited mechanistic data from human tissue. The translational path from cuproptosis sensitivity to clinical intervention remains early-stage. Nevertheless, this work meaningfully advances understanding of arsenic carcinogenesis and points toward novel intervention strategies.
Key Findings
- Elevated intracellular taurine is a metabolic hallmark of arsenite-induced keratinocyte malignant transformation.
- METTL3 adds m6A marks to SLC6A6 mRNA; YTHDF1 binding stabilizes it, boosting taurine transporter expression.
- SLC6A6-driven taurine uptake upregulates MT-CO2, enhancing mitochondrial oxidative phosphorylation to fuel transformation.
- The same MT-CO2-copper axis sensitizes arsenite-transformed cells to cuproptosis, revealing a therapeutic vulnerability.
- Findings were validated across keratinocyte models, mouse models, and human samples.
Methodology
The study used in vitro keratinocyte transformation models with environmentally relevant arsenite concentrations, supplemented by mouse model validation and human sample analysis. Mechanistic dissection employed epitranscriptomic profiling, metabolomics, and functional knockdown/overexpression experiments targeting METTL3, YTHDF1, SLC6A6, and MT-CO2.
Study Limitations
Findings are primarily based on cell culture and mouse models; direct mechanistic validation in human skin cancer tissue is limited. The clinical feasibility of targeting cuproptosis selectively in arsenic-exposed individuals has not been tested. Environmental exposure conditions in models may not fully replicate the complexity of chronic human arsenic exposure.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.